JP2021514373A5 - - Google Patents

Info

Publication number
JP2021514373A5
JP2021514373A5 JP2020544238A JP2020544238A JP2021514373A5 JP 2021514373 A5 JP2021514373 A5 JP 2021514373A5 JP 2020544238 A JP2020544238 A JP 2020544238A JP 2020544238 A JP2020544238 A JP 2020544238A JP 2021514373 A5 JP2021514373 A5 JP 2021514373A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
group
substituted
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020544238A
Other languages
English (en)
Japanese (ja)
Other versions
JP7313364B2 (ja
JP2021514373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/054208 external-priority patent/WO2019162323A1/en
Publication of JP2021514373A publication Critical patent/JP2021514373A/ja
Publication of JP2021514373A5 publication Critical patent/JP2021514373A5/ja
Application granted granted Critical
Publication of JP7313364B2 publication Critical patent/JP7313364B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020544238A 2018-02-21 2019-02-20 Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体 Active JP7313364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18157881 2018-02-21
EP18157881.6 2018-02-21
PCT/EP2019/054208 WO2019162323A1 (en) 2018-02-21 2019-02-20 New benzimidazole compounds and derivatives as egfr inhibitors

Publications (3)

Publication Number Publication Date
JP2021514373A JP2021514373A (ja) 2021-06-10
JP2021514373A5 true JP2021514373A5 (cg-RX-API-DMAC7.html) 2022-03-03
JP7313364B2 JP7313364B2 (ja) 2023-07-24

Family

ID=61256692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020544238A Active JP7313364B2 (ja) 2018-02-21 2019-02-20 Egfr阻害剤としての新たなベンズイミダゾール化合物および誘導体

Country Status (5)

Country Link
US (1) US11174245B2 (cg-RX-API-DMAC7.html)
EP (1) EP3755694B1 (cg-RX-API-DMAC7.html)
JP (1) JP7313364B2 (cg-RX-API-DMAC7.html)
CN (1) CN111741954B (cg-RX-API-DMAC7.html)
WO (1) WO2019162323A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102267662B1 (ko) * 2019-11-19 2021-06-22 한국화학연구원 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR20220114615A (ko) * 2019-12-16 2022-08-17 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Egfr 키나제의 분해를 억제 및 유도하는 화합물
CN113880804A (zh) * 2020-07-01 2022-01-04 微境生物医药科技(上海)有限公司 新型苯并咪唑化合物
CN114057770B (zh) * 2020-08-06 2023-05-02 成都先导药物开发股份有限公司 靶向egfr蛋白降解的双功能化合物
CA3194824A1 (en) * 2020-10-07 2022-04-14 Dana Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
JP7805363B2 (ja) * 2020-11-02 2026-01-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング EGFR阻害薬としての置換1H-ピラゾロ[4,3-c]及び誘導体
CN116761603A (zh) * 2021-02-06 2023-09-15 正大天晴药业集团股份有限公司 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023001069A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 大环酰胺类化合物及其应用
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
AR131026A1 (es) * 2022-11-10 2025-02-12 Beigene Ltd Compuestos para la degradación de la egfr quinasa
AU2024387082A1 (en) 2023-11-21 2026-06-04 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
CN119019366A (zh) * 2024-08-19 2024-11-26 广州医科大学附属第五医院(广州再生医学与健康广东省实验室附属医院) 一种肺癌细胞靶向治疗药物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
EA200400595A1 (ru) 2001-11-09 2004-10-28 Бёрингер Ингельхайм Фармасьютиклз, Инк. Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JP2005536533A (ja) 2002-08-08 2005-12-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 置換ベンゾイミダゾール化合物
US20050176792A1 (en) 2004-01-14 2005-08-11 Boehringer Ingelheim Pharmaceuticals, Inc. Ketone substituted benzimidazole compounds
WO2005079791A1 (en) 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
US20110071130A1 (en) 2006-05-08 2011-03-24 Pharmacopeia, Inc. 2-aminobenzimidazoles for treating neurodegenerative diseases
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
US20150152083A1 (en) 2012-06-06 2015-06-04 Irm Llc, A Delaware Limited Liability Company Compounds and Compositions for Modulating EGFR Activity
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
CA2943231C (en) * 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
IL291000B2 (en) * 2014-03-20 2024-04-01 Capella Therapeutics Inc Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
WO2016176473A1 (en) 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
WO2016185333A1 (en) 2015-05-15 2016-11-24 Novartis Ag Methods for treating egfr mutant cancers
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR102670695B1 (ko) * 2015-09-18 2024-06-05 메르크 파텐트 게엠베하 Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도
ES2911888T3 (es) 2015-09-18 2022-05-23 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos

Similar Documents

Publication Publication Date Title
CA2705294C (en) Methods of treating arthritis by the administration of substituted benzenesulfonamides
TWI770552B (zh) 喹唑啉化合物
RU2006112428A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2021532154A (ja) 抗hiv化合物
DK2953948T3 (en) FLUORINATED INTEGRIN ANTAGONISTS
JP2013532652A5 (cg-RX-API-DMAC7.html)
JP2025071130A5 (cg-RX-API-DMAC7.html)
JP2016509047A5 (cg-RX-API-DMAC7.html)
JP2020514318A5 (cg-RX-API-DMAC7.html)
RU2014115476A (ru) Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ
EA035478B1 (ru) ПРОИЗВОДНЫЕ ДИАРИЛМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ p38
RU2006112427A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2020500866A5 (cg-RX-API-DMAC7.html)
JP2016527217A5 (cg-RX-API-DMAC7.html)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2005538099A5 (cg-RX-API-DMAC7.html)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2022501370A5 (cg-RX-API-DMAC7.html)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2022500425A5 (cg-RX-API-DMAC7.html)
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2019505529A5 (cg-RX-API-DMAC7.html)
JPH04506215A (ja) モノカイン活性干渉
RU2019135261A (ru) Фармацевтическая композиция, содержащая ингибитор pde9